Rovita GmbH is specialized in the development and production of protein and starch derivatives, functional additives and fermentation products for the food processing industry, in particular for meat and sausage products as well as for vegan foods. The company operates two spray-drying plants to produce whey protein concentrate with 35, 60 and 80 % protein and two roller-drying plants to produce caseinate and Quellstaerke, and provides toll-manufacturing services for plant proteins, hydrolysates and collagen products. Fermentation capacities for the production of natural acids with biocidal properties are available; this area is described in the report as strategically important and is being further expanded. The Wiesmuehl plant was acquired in 2018 as part of an asset deal and is leased long-term from the shareholder.
Entwicklung, Herstellung und Vermarktung von Produkten für die Pharma-, die Kosmetik- und die Lebensmittelindustrie, Vermarktung an Endverbraucher eingeschlossen
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Kiel Local Court, HRB 16530 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Steffen Rode | Geschäftsführer(in) | Winsen |
| Darius Smyczek | Geschäftsführer(in) | Babensham |
| Markus Veen | Geschäftsführer(in) | Mühldorf |
Source: German Commercial Register (Handelsregister) Kiel Local Court, HRB 16530 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €32,690,034 | €797,069 | €18,457,345 | — |
| 2023 | €29,845,667 | €595,752 | €16,166,898 | — |
| 2022 | Rohergebnis€10.2M2 | €570,598 | €12,981,644 | — |
| 2021 | Rohergebnis€8.6M2 | €382,592 | €10,703,034 | — |
| 2020 | Rohergebnis€8.4M2 | -€8,800 | €7,770,125 | — |
| 2019 | Rohergebnis€7.3M2 | -€882,104 | €8,301,094 | — |
| 2018 | — | €12,665 | €5,846,828 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Kiel Local Court, HRB 16530 (as of 1 November 2026)
Elementis Pharma GmbH
Ludwigshafen · Herstellung von pharmazeutischen Grundstoffen
MedSkin Solutions Dr. Suwelack AG
Billerbeck · Herstellung von Körperpflegemitteln und Duftstoffen
CLARINS, Gesellschaft mit beschränkter Haftung
Starnberg · Großhandel mit kosmetischen Erzeugnissen und Körperpflegemitteln
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €6,700,055 | 24.5% |
| Material Costs | €19,576,875 | 71.7% |
| Depreciation | €619,824 | 2.3% |
| Interest & Similar | €425,472 | 1.6% |
